Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Jagannath, Sundar
Lee, Hans C.
Richter, Joshua Ryan
Zonder, Jeffrey A.
Hoffman, James E.
Zhou, Zheng-Yi
Horton, Viviana Garcia
Fillbrunn, Mirko
Wang, Hongjue
Mattera, Matthew
Ma, Qiufei
Inocencio, Timothy J.
Xu, Yingxin
Bergrath, Evelien
Harnett, James
Roccia, Tito
Kroog, Glenn Scott
Rodriguez-Lorenc, Karen
Houvras, Yariv
Bumma, Naresh
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[3] Karmanos Canc Inst, Detroit, MI USA
[4] Univ Miami Hlth Syst, Miami, FL USA
[5] Anal Grp Inc, Boston, MA USA
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7560
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma
    Atieh, Tahani
    Atrash, Shebli
    Ahmed, Nausheen
    Mohan, Meera
    Cui, Wei
    Shune, Leyla
    Hajjar, Susana
    Mahmoudjafari, Zahra
    Quick, Julie
    Wishna, Anne
    Riffel, Justin
    McGuirk, Joseph
    Mohyuddin, Ghulam Rehman
    Abdallah, Al-Ola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (12): : 912 - 919
  • [42] Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
    Maringanti, Sireesha Asoori
    Lin, Yi
    Estritis, Stathis
    Martinez-Lopez, Joaquin
    Bansal, Radhika
    Fotiou, Despina
    Corona, Magdalena
    Chhabra, Saurabh
    Brunaldi, Larissa
    Corraes, Andre De Menezes Silva
    Parrondo, Ricardo
    Kapoor, Prashant
    Ailawadhi, Sikander
    Mas, Reyes
    Tamayo, Andrea
    Dimopoulos, Meletios
    Durie, Brian
    Martin, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S506 - S507
  • [43] Preferences among patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) in the era of B-cell maturation antigen (BCMA)-directed T-cell-engaging therapies
    Ailawadhi, Sikander
    Inocencio, Timothy J.
    Mansfield, Carol
    Chintakayala, Phani
    Bussberg, Cooper
    Chi, Lei
    Harnett, James
    Kroog, Glenn Scott
    Houvras, Yariv
    Rodriguez-Lorenc, Karen
    Ma, Qiufei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma
    Mol, Isha
    Hu, Yannan
    Leblanc, Thomas W.
    Cappelleri, Joseph C.
    Chu, Haitao
    Nador, Guido
    Aydin, Didem
    Schepart, Alex
    Hlavacek, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (02) : 199 - 207
  • [45] Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-Class Relapsed/Refractory Multiple Myeloma (RRMM): A Single-Institution Experience
    Pennipede, Dante
    Mohyuddin, Ghulam Rehman
    Hawkins, Ryan
    Ganguly, Siddhartha
    Shune, Leyla
    Ahmed, Nausheen
    Mohan, Meera
    Cui, Wei
    Mahmoudjafari, Zahra
    McGuirk, Joseph
    Atrash, Shebli
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S434 - S435
  • [46] Preferences Among Patients With Triple-Class Exposed (TCE) Relapsed/ Refractory Multiple Myeloma (RRMM) in the Era of B-Cell Maturation Antigen (BCMA)-Directed T-Cell-Engaging Therapies
    Ailawadhi, Sikander
    Inocencio, Timothy J.
    Mansfield, Carol
    Chintakayala, Phani
    Bussberg, Cooper
    Chi, Lei
    Harnett, James
    Kroog, Glenn
    Houvras, Yariv
    Rodriguez-Lorenc, Karen
    Ma, Qiufei
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S554 - S554
  • [47] A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma
    Mol, Isha
    Hu, Yannan
    LeBlanc, Thomas W.
    Cappelleri, Joseph C.
    Chu, Haitao
    Nador, Guido
    Aydin, Didem
    Schepart, Alex
    Hlavacek, Patrick
    BLOOD, 2023, 142
  • [48] Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma
    Mol, Isha
    Hu, Yannan
    Leblanc, Thomas W.
    Cappelleri, Joseph C.
    Chu, Haitao
    Nador, Guido
    Aydin, Didem
    Perez-Cruz, Isabel
    Hlavacek, Patrick
    BLOOD, 2024, 144 : 7028 - 7029
  • [49] Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Popat, Rakesh
    Martinez-Lopez, Joaquin
    Kastritis, Efstathios
    Brunaldi, Larissa
    Bansal, Radhika
    Corraes, Andre De Menezes Silva
    Yong, Kwee
    Mactier, Catriona
    Corona, Magdalena
    Saez Marin, Adolfo Jesus
    Fotiou, Despina
    Dimopoulos, Meletios Athanasios
    Chhabra, Saurabh
    Ailawadhi, Sikander
    Parrondo, Ricardo
    Martin, Thomas
    Durie, Brian G. M.
    Lin, Yi
    BLOOD, 2023, 142
  • [50] An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma
    Otero, Paula Rodriguez
    Towle, Kevin
    Cope, Shannon
    Caisip, Clyde
    Davies, Faith E.
    Delforge, Michel
    Weisel, Katja
    Marshall, Thomas S.
    Karampampa, Korinna
    Ayers, Dieter
    Mojebi, Ali
    Braverman, Julia
    Farrell, James
    Dhanda, Devender
    LEUKEMIA & LYMPHOMA, 2023, 64 (11) : 1864 - 1869
12345